Pfizer (PFE) Net Income (2009 - 2026)
Pfizer (PFE) reported Net Income of -$13.0 million for Q1 2026, down 152.0% quarter-over-quarter from $25.0 million in Q2 2025.
Pfizer (PFE) Net Income (2009 - 2026) Analysis & Trends
Pfizer (PFE) has 18 years of Net Income data on file, last reported at -$13.0 million in Q1 2026.
- Net Income for Q1 2026 came in at -$13.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (up 33.33% YoY), and the FY2025 annual result was $25.0 million, up 127.27% from the prior year.
- Net Income retreated to -$13.0 million in Q1 2026 per PFE's latest filing, from $25.0 million in the prior quarter.
- Over five years, Net Income peaked at $34.0 million in Q3 2022 and troughed at -$26.0 million in Q4 2023.
- A 5-year average of $416666.7 and a median of -$3.5 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income slumped 1000.0% in 2022, then soared 950.0% in 2024.
- A 5-year view of Net Income shows it stood at -$21.0 million in 2022, then slipped by 23.81% to -$26.0 million in 2023, then soared by 69.23% to -$8.0 million in 2024, then jumped by 412.5% to $25.0 million in 2025, then sank by 152.0% to -$13.0 million in 2026.
- Business Quant data shows PFE's Net Income at -$13.0 million in Q1 2026, $25.0 million in Q2 2025, and -$8.0 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -13.00 Mn |
| Jun 29, 2025 | 25.00 Mn |
| Sep 29, 2024 | -8.00 Mn |
| Jun 30, 2024 | 17.00 Mn |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Oct 1, 2023 | 12.00 Mn |
| Jul 2, 2023 | -2.00 Mn |
| Apr 2, 2023 | 1.00 Mn |
| Oct 2, 2022 | -21.00 Mn |
| Jul 3, 2022 | 34.00 Mn |
| Apr 3, 2022 | -9.00 Mn |
| Oct 3, 2021 | -13.00 Mn |
| Jul 4, 2021 | -236.00 Mn |
| Apr 4, 2021 | 1.00 Mn |
| Sep 27, 2020 | 560.00 Mn |
| Jun 28, 2020 | 893.00 Mn |
| Mar 29, 2020 | 881.00 Mn |
| Dec 31, 2019 | 5.31 Bn |
| Sep 29, 2019 | 4.00 Mn |